Gilead Sciences GILD
NASDAQ GILD
$144.80 -0.85 (-0.58%)
As of: Sep 10, 2026 · 3:59 PM EDT

Gilead Sciences (GILD) Intangibles (2009 - 2026)

Gilead Sciences' (GILD) quarterly Intangibles came in at $14.0 billion in Q2 2026, down 24.42% on a YoY basis from $18.6 billion in Q2 2025, and down 14.35% quarter-over-quarter from $16.4 billion in Q1 2026.

Analysis

Gilead Sciences (GILD) Intangibles (2009 - 2026) Analysis & Trends

Gilead Sciences (GILD) has reported Intangibles for 18 consecutive years, with $14.0 billion the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Intangibles fell 24.42% year-over-year to $14.0 billion; the trailing twelve-month figure through Jun 2026 stood at $14.0 billion (down 24.42% YoY), and the FY2025 full-year result was $17.0 billion, down 14.89% from the prior year.
  • Intangibles declined to $14.0 billion in Q2 2026 per GILD's latest filing, from $16.4 billion in the prior quarter.
  • Across five years, Intangibles topped out at $30.3 billion in Q1 2022 and bottomed at $14.0 billion in Q2 2026.
  • Historically, Intangibles has averaged $23.2 billion across 5 years, with a median of $23.1 billion in 2024.
  • The sharpest annual moves came in 2023 and 2024: Intangibles dropped 6.54% in 2023, then declined 24.59% in 2024.
  • Over 5 years, Intangibles stood at $28.9 billion in 2022, then slipped by 8.44% to $26.5 billion in 2023, then fell by 24.59% to $19.9 billion in 2024, then retreated by 14.89% to $17.0 billion in 2025, then dropped by 17.35% to $14.0 billion in 2026.
  • According to Business Quant data, Intangibles over the past three periods registered $14.0 billion, $16.4 billion, and $17.0 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Intangibles (Qtr)
1 Amgen 206.44 Bn 192.45 Bn 7.24 Bn 20.49 Bn
2 Gilead Sciences 179.97 Bn 176.79 Bn 6.22 Bn 14.03 Bn
3 Vertex Pharmaceuticals 130.57 Bn 122.72 Bn 2.84 Bn 412.80 Mn
4 Regeneron Pharmaceuticals 81.63 Bn 73.63 Bn 3.93 Bn 1.31 Bn
5 Argenx Se 60.34 Bn 55.16 Bn 1.37 Bn 266.00 Mn
6 Moderna 54.37 Bn 49.23 Bn 52.00 Mn -
7 Alnylam Pharmaceuticals 33.07 Bn 29.76 Bn 992.69 Mn -
8 Biogen 31.84 Bn 30.55 Bn 1.96 Bn 13.52 Bn
9 Roivant Sciences 29.49 Bn 29.49 Bn 1.16 Mn -
10 Insmed 27.67 Bn 26.51 Bn 358.27 Mn 93.49 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 14.03 Bn
Mar 31, 2026 16.38 Bn
Dec 31, 2025 16.98 Bn
Sep 30, 2025 17.97 Bn
Jun 30, 2025 18.57 Bn
Mar 31, 2025 19.36 Bn
Dec 31, 2024 19.95 Bn
Sep 30, 2024 20.55 Bn
Jun 30, 2024 22.83 Bn
Mar 31, 2024 23.43 Bn
Dec 31, 2023 26.45 Bn
Sep 30, 2023 27.15 Bn
Jun 30, 2023 27.75 Bn
Mar 31, 2023 28.35 Bn
Dec 31, 2022 28.89 Bn
Sep 30, 2022 29.44 Bn
Jun 30, 2022 29.89 Bn
Mar 31, 2022 30.33 Bn
Dec 31, 2021 33.46 Bn
Sep 30, 2021 33.90 Bn